Your browser doesn't support javascript.
loading
Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients
Ríos, I; Rovirosa, A; Ascaso, C; Valduvieco, I; Herreros, A; Castilla, L; Sabater, S; Holub, K; Pahisa, J; Biete, A; Arenas, M.
Affiliation
  • Ríos, I; Centro Medico Imbanaco. Cancer Institute. Radiation Oncology Department. Cali. Colombia
  • Rovirosa, A; Hospital Clinic Universitari. Functional Gynecologic Cancer Unit. Barcelona. Spain
  • Ascaso, C; Universitat de Barcelona. Medicine Faculty. Public and Health Department. Barcelona. Spain
  • Valduvieco, I; Hospital Clinic Universitari. Functional Gynecologic Cancer Unit. Barcelona. Spain
  • Herreros, A; Hospital Clinic Universitari. Functional Gynecologic Cancer Unit. Barcelona. Spain
  • Castilla, L; Hospital Clinic Universitari. Functional Gynecologic Cancer Unit. Barcelona. Spain
  • Sabater, S; Hospital General de Albacete. Radiation Oncology Department. Albacete. Spain
  • Holub, K; Hospital Clinic Universitari. Functional Gynecologic Cancer Unit. Barcelona. Spain
  • Pahisa, J; Hospital Clinic I Universitari. Functional Gynecologic Cancer Unit. Barcelona. Spain
  • Biete, A; Hospital Clinic Universitari. Functional Gynecologic Cancer Unit. Barcelona. Spain
  • Arenas, M; Hospital Sant Joan de Reus. Radiation Oncology Department. Reus. Spain
Clin. transl. oncol. (Print) ; 18(9): 925-930, sept. 2016. tab
Article in En | IBECS | ID: ibc-155507
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
PURPOSE: To analyze the vaginal-cuff local control (VCC) and toxicity in postoperative endometrial carcinoma patients (EC) underwent high-dose-rate brachytherapy (HDR-BT) administered daily. Materials and methods: 154 consecutive patients received postoperative HDR-BT for EC from January 2007 to September 2011. FIGO-staging I-IIIC2 patients were divided into two groups according to risk classification: Group 1 (94/154) included high-risk or advanced disease patients and Group 2 (60/154) included intermediate-risk EC patients. Group 1 underwent external beam irradiation (EBI) plus HDR-BT (2 fractions of 5 Gy) and Group 2 underwent HDR-BT alone (4 fractions of 5 Gy). Toxicity evaluation was done with RTOG scores for bladder and rectum, and the objective criteria of LENT-SOMA for vagina. Results: With a median follow-up of 46.7 months (36.6-61 months) only two patients developed vaginal-cuff recurrence in Group 1 (2.1 %) and none in group 2 (0 %). Early toxicity in Group 1 appeared 5.3 % in rectum, 7.5 % in bladder (G1-G2) and 2.1 % in vagina (G1); late toxicity was present in 7.3 % in rectum (all G1-G2 but 1 G3) and in 27.7 % in vagina (all G1-G2 but one G4). In Group 2, 6.7 % developed acute G1-G2 bladder and 6.6 % acute vaginal (G1-G2) toxicity. No late rectal or bladder toxicity was observed; 21.7 % of G1-G2 presented late problems in vagina. Conclusions: The present HDR-BT schedule of 2 fractions of 5 Gy after EBI and 4 fractions of 5 Gy administered daily showed excellent results in terms of VCC and toxicity
RESUMEN
No disponible
Subject(s)
Search on Google
Collection: 06-national / ES Database: IBECS Main subject: Brachytherapy / Endometrial Neoplasms Limits: Female / Humans Language: En Journal: Clin. transl. oncol. (Print) Year: 2016 Document type: Article
Search on Google
Collection: 06-national / ES Database: IBECS Main subject: Brachytherapy / Endometrial Neoplasms Limits: Female / Humans Language: En Journal: Clin. transl. oncol. (Print) Year: 2016 Document type: Article